Bouchmaa Najat, Mrid Reda Ben, Boukharsa Youness, Bouargalne Youssef, Nhiri Mohamed, Idir Abderrazak, Taoufik Jamal, Ansar Mʼhammed, Zyad Abdelmajid
Laboratory of Medicinal Chemistry, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.
Team of Experimental Oncology and Natural Substances, Cellular and Molecular Immuno-pharmacology, Faculty of Science and Technology, Sultan Moulay Slimane University, Beni-Mellal, Morocco.
Drug Res (Stuttg). 2019 Oct;69(10):528-536. doi: 10.1055/a-0762-3775. Epub 2019 Jun 28.
In cancer cells, the intracellular antioxidant capacity and the redox homeostasis are mainly maintained by the glutathione- and thioredoxin-dependent systems which are considered as promising targets for anticancer drugs. Pyridazinones constitute an interesting source of heterocyclic compounds for drug discovery. The present investigation focused on studying the in-vitro antitumor activity of newly synthesized Pyridazin-3(2h)-ones derivatives against P815 (Murin mastocytoma) cell line.
The in-vitro cytotoxic activities were investigated toward the P815 cell line using tetrazolium-based MTT assay. Lipid peroxidation and the specific activities of antioxidant enzymes were also determined.
The newly compounds had a selective dose-dependent cytotoxic effect without affecting normal cells (PBMCs). Apoptosis was further confirmed through the characteristic apoptotic morphological changes and DNA fragmentation. Two compounds (6F: and 7H: ) were highly cytotoxic and were submitted to extend biological testing to determine the likely mechanisms of their cytotoxicity. Results showed that these molecules may induce cytotoxicity via disturbing the redox homeostasis. Importantly, the anticancer activity of 6F: and 7H: could be due to the intracellular reactive oxygen species hypergeneration through significant loss of glutathione reductase and thioredoxin reductase activities. This eventually leads to oxidative stress-mediated P815 cell apoptosis. Furthermore, the co-administration of 6F: or 7H: with Methotrexate exhibited a synergistic cytotoxic effect.
considering their significant anticancer activity and chemosensitivity, 6F: and 7H: may improve the therapeutic efficacy of the current treatment for cancer.
在癌细胞中,细胞内抗氧化能力和氧化还原稳态主要由谷胱甘肽和硫氧还蛋白依赖系统维持,这些系统被认为是抗癌药物的有前景的靶点。哒嗪酮是药物发现中有趣的杂环化合物来源。本研究聚焦于研究新合成的哒嗪 - 3(2H)- 酮衍生物对P815(鼠肥大细胞瘤)细胞系的体外抗肿瘤活性。
使用基于四唑盐的MTT法研究对P815细胞系的体外细胞毒性活性。还测定了脂质过氧化和抗氧化酶的比活性。
新化合物具有选择性剂量依赖性细胞毒性作用,而不影响正常细胞(外周血单核细胞)。通过特征性的凋亡形态变化和DNA片段化进一步证实了凋亡。两种化合物(6F和7H)具有高度细胞毒性,并进行了扩展的生物学测试以确定其细胞毒性的可能机制。结果表明,这些分子可能通过扰乱氧化还原稳态诱导细胞毒性。重要的是,6F和7H的抗癌活性可能是由于谷胱甘肽还原酶和硫氧还蛋白还原酶活性的显著丧失导致细胞内活性氧超量产生。这最终导致氧化应激介导的P815细胞凋亡。此外,6F或7H与甲氨蝶呤联合给药表现出协同细胞毒性作用。
考虑到它们显著的抗癌活性和化学敏感性,6F和7H可能提高当前癌症治疗的疗效。